Affordable Access

deepdyve-link
Publisher Website

Population Pharmacokinetics of Dexmedetomidine in Infants.

Authors
  • Greenberg, Rachel G1, 2
  • Wu, Huali2
  • Laughon, Matthew3
  • Capparelli, Edmund4
  • Rowe, Stevie1
  • Zimmerman, Kanecia O1, 2
  • Smith, P Brian1, 2
  • Cohen-Wolkowiez, Michael1, 2
  • 1 Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
  • 2 Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
  • 3 Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • 4 Department of Pediatrics and Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, CA, USA.
Type
Published Article
Journal
Journal of clinical pharmacology
Publication Date
Sep 01, 2017
Volume
57
Issue
9
Pages
1174–1182
Identifiers
DOI: 10.1002/jcph.904
PMID: 28444697
Source
Medline
Keywords
License
Unknown

Abstract

Despite limited pharmacokinetic (PK) data, dexmedetomidine is increasingly being used off-label for sedation in infants. We aimed to characterize the developmental PK changes of dexmedetomidine during infancy. In this open-label, single-center PK study of dexmedetomidine in infants receiving dexmedetomidine per clinical care, ≤10 blood samples per infant were collected. A set of structural PK models and residual error models were explored using nonlinear mixed-effects modeling in NONMEM. Covariates including postmenstrual age (PMA), serum creatinine, and recent history of cardiac surgery requiring cardiopulmonary bypass were investigated for their influence on PK parameters. Univariable generalized estimating equation models were used to evaluate the association of hypotension with dexmedetomidine concentrations. A total of 89 PK samples were collected from 20 infants with a median PMA of 44 weeks (range, 33-61). The median maximum dexmedetomidine infusion dose during the study period was 1.8 μg/(kg·h) (0.5-2.5), and 16/20 infants had a maximum dose >1 μg/(kg·h). A 1-compartment model best described the data. Younger PMA was a significant predictor of lower clearance. Infants with a history of cardiac surgery had ∼40% lower clearance compared to those without a history of cardiac surgery. For infants with PMA of 33 to 61 weeks and body weight of 2 to 6 kg, the estimated clearance and volume of distribution were 0.87 to 2.65 L/(kg·h) and 1.5 L/kg, respectively. No significant associations were found between dexmedetomidine concentrations and hypotension. Infants with younger PMA and recent cardiac surgery may require relatively lower doses of dexmedetomidine to achieve exposure similar to older patients and those without cardiac surgery.

Report this publication

Statistics

Seen <100 times